ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center open-label phase I clinical trial of delivering haploidentical
natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of
ALT-801 in patients with relapsed/refractory Acute Myeloid Leukemia (AML). The study will be
conducted at M.D. Anderson Cancer Center (MDACC) and MDACC Children's Cancer Hospital in
Houston, Texas.